Compare Duolingo Inc (DUOL) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Mesoblast Limited — how do they compare? Duolingo Inc trades at $135 (market cap $6.34B), while Mesoblast Limited trades at $16.98 (market cap $2.21B). The key difference: Duolingo Inc is far larger — about 2.9× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Duolingo Inc nearer its low. Which is the better fit depends on your goals.
| DUOL | MESO | |
|---|---|---|
Market Cap | $6.34B | $2.21B |
Sector | Technology | Technology |
52-Week High | $369.19 | $20.96 |
52-Week Low | $90.03 | $12.88 |
Enterprise Value | $5.11B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $132.75, down 3.24% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.66 versus $0.604 expected, driven by 23% daily active user growth. Revenue reached $1.04 billion in 2025, with net income surging to $414 million, though Q3 2026 revenue guidance fell short of expectations, causing recent stock pressure.
The investment outlook is mixed: robust user growth and profitability metrics like a 35.87% net margin support upside, but decelerating bookings growth and margin pressures from AI investments pose risks. Analysts show cautious optimism with a $121 consensus target, highlighting the stock's sensitivity to monetization trends amid competitive threats.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
